


PHARMACEUTICAL 2023

Verona Pharma plc Rank 73 of 446









PHARMACEUTICAL 2023



Verona Pharma plc Rank 73 of 446



The relative strengths and weaknesses of Verona Pharma plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verona Pharma plc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Verona Pharma plc is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 184% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	242,996
Cost of Goods Sold	346
Intangible Assets	545
Liabilities, Current	19,029
Liabilities, Non-Current	9,973
Other Assets	15,854
Other Compr. Net Income	0
Other Expenses	253
Other Liabilities	0
Other Net Income	7,302
Other Revenues	458
Property and Equipment	73
Research and Development	49,283
Selling, General and Administrative Expense	26,579

Output Variable	Value in 1000 USD
Assets	259,468
Liabilities	29,002
Expenses	76,461
Revenues	458
Stockholders Equity	230,466
Net Income	-68,701
Comprehensive Net Income	-68,701
Economic Capital Ratio	227%

